What Leyden Labs does

Leyden Laboratories B.V. is a Dutch clinical-stage biotechnology company founded in 2020 and headquartered in Amsterdam that develops intranasal antibody-based nasal sprays designed to provide immediate, broad-spectrum protection against respiratory viruses including influenza and coronaviruses. Its lead asset, PanFlu, delivers the broadly neutralizing CR9114 antibody directly to the respiratory mucosa via nasal spray, and demonstrated safety, tolerability, and protective mucosal antibody concentrations in a Phase 1 study of 143 healthy volunteers, with non-human primate studies confirming protection against H1N1 challenge. These data were published in Science Translational Medicine and underpin the company's Mucosal Protection Platform, which positions the technology as a non-vaccine, mutation-resilient alternative to traditional flu vaccines that average roughly 13% effectiveness against infection.

The company has raised approximately $358 million+ cumulatively since inception, anchored by a $140-200 million 2021/2022 Series B led by Casdin Capital and GV (with SoftBank Vision Fund, F-Prime, Invus, Polaris Partners, Qiming Venture Partners and others), supplemented by 2025-2026 tranches from the European Investment Bank (€20M debt, HERA-facilitated), the European Innovation Council Fund and Invest-NL (€30M; €40M), and the Gates Foundation Strategic Investment Fund alongside ClavystBio. In January 2025 the company acquired CoV Biotechnology to extend its pandemic preparedness footprint into Asia. Investors have signaled a pre-money valuation of approximately $800M during the Series B, implying an estimated ~$1B post-money valuation.

Commercially, Leyden Labs is pre-revenue with no products approved. Its go-to-market strategy targets healthcare provider and government procurement channels for pandemic preparedness stockpiling, alongside a global public health / LMIC access pathway enabled by Gates Foundation participation. Distribution is anticipated through hospital and clinic channels, government health authority stockpiling, and international organizations, with supporting GTM motion described as enterprise field sales to public sector and global health buyers. The company is led by Co-Founder/CEO Koenraad Wiedhaup and CSO Clarissa Koch, with Founder Jaap Goudsmit and Founder/CBO Ronald Brus, Executive Chairman Dinko Valerio, and CMO Jintanat Ananworanich providing senior leadership; Ben Verwaayen joined the Supervisory Board in June 2026.

Name

Leyden Labs

Legal name

Leyden Laboratories B.V.

Website

http://www.leydenlabs.com/

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

51–100 employees

Short description

Leyden Labs is a Dutch clinical-stage biotech founded in 2020 developing intranasal antibody nasal sprays, led by PanFlu, which deliver broadly neutralizing antibodies to the respiratory mucosa for immediate protection against influenza and other respiratory viruses, serving governments and global health buyers for pandemic preparedness.

Ownership category

akta.pro rank

Product category

Infectious Disease Prophylactics

akta.pro primary industry

Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC)

akta.pro secondary industries

Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral) (HLAAAEAF), Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA), Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD), Pandemic Preparedness & Rapid-Response Vaccines (HLAIAEAF), Nasal Drug Delivery Devices (Sprays/Powder Devices) (HLAHAIAK)

Keywords

• Intranasal antibody therapy
• Respiratory virus prophylaxis
• Pandemic preparedness solutions
• Broadly neutralizing antibodies
• Mucosal protection platform

Headquarters

HQ city

Amsterdam

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Pharmaceutical Product Sales: Leyden Labs is developing and advancing toward commercialization of its intranasal antibody nasal spray products (PanFlu) for influenza and other respiratory virus prevention. The company aims to bring these products to market as prophylactic treatments for healthcare providers, governments, and potentially consumers for pandemic preparedness.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Leyden Labs develops intranasal antibody-based nasal sprays that deliver broadly neutralizing antibodies directly to the respiratory mucosa to provide immediate, broad-spectrum protection against respiratory viruses including influenza and coronaviruses. The company's lead candidate, PanFlu, uses the CR9114 antibody and is advancing through clinical trials toward regulatory approval and commercialization for pandemic preparedness and public health use.

Product overview

Leyden Labs is developing a portfolio of intranasal antibody-based products targeting respiratory viruses. The company's lead product is PanFlu, an antibody-based nasal spray using the broadly neutralizing CR9114 antibody. This is enabled by the company's Mucosal Protection Platform technology, which delivers protective antibodies directly to the nasal mucosa. The products aim to provide immediate, broad-spectrum protection against influenza, coronaviruses, and other respiratory viruses at the point of viral entry.

Differentiator

Problem solved

Functional benefit

Brands

• PanFlu: Intranasal spray candidate delivering broadly neutralizing CR9114 antibody for protection against influenza and other respiratory viruses at the point of viral entry.
• Mucosal Protection Platform

Products and services

• PanFlu An antibody-based intranasal nasal spray for influenza prevention that delivers the broadly neutralizing CR9114 antibody directly to the respiratory mucosa. Phase 1 clinical studies demonstrated safety, tolerability, and protective antibody concentrations in 143 healthy volunteers, with non-human primate studies confirming protection against H1N1 infection and reduced viral load. Targeted at healthcare providers, governments, and global public health programs for pandemic preparedness.
• Mucosal Protection Platform A technology platform that delivers broadly protective antibodies directly to the respiratory mucosa (nose and throat) to provide immediate protection against respiratory viruses including influenza and coronaviruses. Underpins Leyden Labs' intranasal product pipeline, including the lead candidate PanFlu.

Quantifiable outcome

• Phase 1 studies (n=143 healthy volunteers) demonstrated that intranasal delivery of CR9114 antibody was safe, well-tolerated, and achieved protective concentrations in nasal mucosa
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered minor and core.

• Ben Verwaayen (Supervisory Board Member)minorOthers · 26 June 2026Appointed to the Supervisory Board, bringing international leadership experience from senior executive roles at global technology companies. Nominated by EIC Fund and Invest-NL.
• CoV Biotechnology (Covbio)coreStrategic or Co-development Partner · 9 January 2025Acquired CoV Biotechnology to strengthen Leyden Labs' pandemic preparedness efforts in Asia. The acquisition expands the company's capabilities and geographic footprint in Asian markets for respiratory virus protection.
• HERA (European Health Emergency Preparedness and Response Authority)coreStrategic or Co-development Partner · 1 January 2025Facilitated the €20 million EIB investment to advance Leyden Labs' intranasal antibody approach for pandemic preparedness in Europe. Represents a strategic alignment with European public health preparedness priorities.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Moderna: Moderna is a leading mRNA vaccine and therapeutics company developing respiratory virus vaccines including mRNA-1010 and mRNA-1083 (flu+COVID combinations). It competes with Leyden Labs for the same pandemic preparedness and seasonal flu prophylaxis market, but with a fundamentally different technology platform (mRNA vs intranasal antibodies).
• BioNTech: BioNTech is a leading mRNA therapeutics company with COVID and influenza vaccine programs and a broad oncology and infectious disease pipeline. It is comparable to Leyden Labs as a competing modality addressing the same pandemic preparedness and respiratory virus prophylaxis use cases.
• Regeneron Pharmaceuticals: Regeneron is a leading monoclonal antibody company whose REGN-COV2 (casirivimab/imdevimab) demonstrated the feasibility of antibody-based prophylaxis for respiratory viruses. As a large biotech with established mAb manufacturing, it represents both a potential competitor and likely strategic acquirer of intranasal antibody programs like Leyden's.
• AstraZeneca: AstraZeneca developed Evusheld (tixagevimab/cilgavimab), the leading antibody prophylaxis for COVID-19 in immunocompromised patients. It is comparable to Leyden Labs as a competing prophylactic mAb franchise targeting pandemic preparedness stockpiling budgets.
• CSL Seqirus: CSL Seqirus is one of the world's largest influenza vaccine manufacturers and a major pandemic preparedness partner to governments. It is comparable to Leyden Labs as the incumbent channel and likely competitor/distributor for intranasal antibody products in government stockpiling markets.

Direct peers

• Vir Biotechnology: Vir Biotechnology is a clinical-stage immunology company developing antibody-based therapeutics for serious infectious diseases including influenza (sotrovimab, VIR-2482) and COVID-19. It is the closest direct peer to Leyden Labs, pursuing prophylactic monoclonal antibodies against respiratory viruses through a different delivery route (intramuscular vs intranasal).
• Arcturus Therapeutics: Arcturus is a clinical-stage mRNA and lipid nanoparticle company developing self-amplifying mRNA vaccines including a pandemic influenza vaccine (ARCT-2138). It is comparable to Leyden Labs as a competing modality addressing the same broad-protection influenza use case.
• CureVac: CureVac is a clinical-stage mRNA company developing vaccines for infectious diseases including seasonal and pandemic influenza (CVSQIV). It competes with Leyden Labs for the same broad-protection respiratory virus market with an alternative technology platform.
• Invivyd (formerly Adagio Therapeutics): Invivyd is a clinical-stage biopharmaceutical company developing antibody-based therapeutics for COVID-19 and other viral diseases, with a focus on durable monoclonal antibodies for prophylaxis. It is directly comparable to Leyden Labs as a competing mAb-focused pandemic preparedness company.

Emerging players

• Hummingbird Bioscience: Hummingbird Bioscience is a clinical-stage biotechnology company developing precision-engineered antibody therapeutics for oncology and infectious diseases. It is comparable to Leyden Labs as a fellow emerging antibody platform company, though focused on different therapeutic areas.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/LeydenLabs

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds9 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Leyden Labs